Sai Ravi Pingali
Overview
Explore the profile of Sai Ravi Pingali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sirimaturos M, Gotur D, Patel S, Dreucean D, Jakowenko N, Cooper M, et al.
Crit Care Explor
. 2020 Oct;
2(10):e0232.
PMID: 33063035
Design: A retrospective cohort analysis of 21-day outcomes for consecutive mechanically ventilated patients treated with tocilizumab from March 24, 2020, to May 4, 2020. Setting: Nine ICUs at six hospitals...
12.
Anand K, Sahu G, Burns E, Ensor A, Ensor J, Pingali S, et al.
ESMO Open
. 2020 Aug;
5(4).
PMID: 32817069
Background: Immune checkpoint inhibitors that block programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have improved outcomes for many cancer subtypes but do exhibit toxicity, in the form...
13.
Kasparian S, Burns E, Shehabeldin A, Awar M, Pingali S
J Med Case Rep
. 2020 Aug;
14(1):127.
PMID: 32782017
Background: Acute small bowel obstruction is a common surgical emergency usually caused by abdominal adhesions, followed by intraluminal tumors from metastatic disease. Although lymphomas have been known to cause bowel...
14.
Gentille C, Anand K, Dalwadi S, Puri A, Farach A, Pingali S
Clin Case Rep
. 2020 Jul;
8(7):1153-1155.
PMID: 32695347
DA-R-EPOCH is used in PMBCL due to its good outcomes without radiation. We present three cases that required consolidation with radiation despite using this regimen. More studies are needed before...
15.
Wang Q, Zhao D, Xian M, Wang Z, Bi E, Su P, et al.
Blood
. 2020 Jun;
136(22):2557-2573.
PMID: 32582913
Multiple myeloma (MM) remains largely incurable despite significant advances in biotherapy and chemotherapy. The development of drug resistance is a major problem in MM management. Macrophage migration inhibitory factor (MIF)...
16.
Burns E, Anand K, Chung B, Shah S, Randhawa J, Pingali S
Ecancermedicalscience
. 2020 Apr;
14:1011.
PMID: 32256694
Secondary acute myeloid leukaemia complicating the natural disease course of pre-existing Philadelphia chromosome-negative myeloproliferative neoplasms (PN-MPN) is well documented and associated with treatment challenges and significant morbidity. The incidence of...
17.
Anand K, Ensor J, Pingali S, Hwu P, Duvic M, Chiang S, et al.
J Immunother Cancer
. 2020 Mar;
8(1).
PMID: 32114498
Background: Murine model suggests programmed cell death-1 (PD-1), an immune checkpoint not only plays role in tumor escape but is also a tumor suppressor for T-cells. But until, no reports...
18.
Anand K, Burns E, Ensor J, Rice L, Pingali S
Clin Lymphoma Myeloma Leuk
. 2019 Nov;
20(1):18-23.
PMID: 31699655
Background: Ruxolitinib is a selective Janus kinase inhibitor (JAKI) 1/2 approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV). These patients may be at risk for developing opportunistic...
19.
Burns E, Gentille C, Kasparian S, Pingali S
Case Rep Hematol
. 2019 Nov;
2019:7834728.
PMID: 31687231
Histiocytic sarcoma (HS) is an uncommon malignant neoplasm arising from mature histiocytes and most commonly characterized by the immunophenotypic expression of CD68, CD163, or lysozyme. Although rare, HS arising as...
20.
Anand K, Pingali S, Trachtenberg B, Iyer S
Case Rep Hematol
. 2019 Jun;
2019:7690430.
PMID: 31214365
Primary cardiac lymphoma (PCL) is a rare extranodal lymphoma involving only the heart and/or the pericardium. Most common presenting signs and symptoms are nonspecific including dyspnea, pericardial effusion, and arrhythmia....